A Journal of Translational Medicine study reported that fratricide‑driven, unedited CD7 CAR‑T cells show therapeutic promise against T‑cell leukemia, leveraging the natural elimination of CD7‑expressing T cells to reduce fratricide-related manufacturing hurdles. The approach avoids complex gene editing while maintaining anti‑leukemia activity in preclinical models. Authors argue the strategy simplifies production and may lower costs versus heavily edited products, but the clinical viability depends on managing on‑target, off‑tumor T‑cell aplasia and ensuring immune reconstitution in patients. Safety strategies could include transient CAR expression or selective depletion controls. Developers in the cell‑therapy space will watch for clinical translation of unedited constructs as a lower‑complexity path to T‑cell malignancy targets.